1d:I[2890,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1e:I[1318,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1f:T41a,

On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo Nordisk’s Chief Scientific Advisor, and led the research group back in the early 1990s that first invented the molecule. A few topics from our conversation:

The science behind what is happening in the body that causes weight loss while on Ozempic
What it was like in the 1990s and 2000s believing in a drug for a problem that the rest of the industry (including her own company) had written off
How weight loss was actually a goal from the very start — not just a side effect of diabetes medication like you often read today!

Sponsors:

Vanta

20:T4f6,[{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Podcasts","item":"https://metacast.app/podcasts"},{"@type":"ListItem","position":2,"name":"Business","item":"https://metacast.app/podcasts/categories/business"},{"@type":"ListItem","position":3,"name":"ACQ2 by Acquired","item":"https://metacast.app/podcasts/b148f9b9-aca8-5861-8bbb-380aaf4db7cc"}]},{"@context":"https://schema.org","@type":"Brea

‌

Episode description

The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)

Episode description